YMAB Historical Financial Ratios
| YMAB Stock | USD 5.09 0.07 1.36% |
Y MAbs is currently reporting on over 93 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Price To Sales Ratio of 3.76, Dividend Yield of 0.0, PTB Ratio of 3.58 or Days Sales Outstanding of 65.86 will help investors to properly organize and evaluate Y mAbs Therapeutics financial condition quickly.
YMAB |
About YMAB Financial Ratios Analysis
Y mAbs TherapeuticsFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Y MAbs investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on YMAB financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Y MAbs history.
Y MAbs Financial Ratios Chart
Add Fundamental
Price To Sales Ratio
Price to Sales Ratio is figured by comparing Y mAbs Therapeutics stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Y MAbs sales, a figure that is much harder to manipulate than other Y mAbs Therapeutics multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.Ptb Ratio
Price-to-Book ratio, a financial valuation metric used to compare a company's current market price to its book value. It provides insight into the value that market participants place on the company's equity relative to its net asset value.Book Value Per Share
The ratio of equity available to common shareholders divided by the number of outstanding shares. This measure represents the value per share of a company according to its financial statements.Most ratios from Y MAbs' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Y mAbs Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Y mAbs Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. At present, Y MAbs' Book Value Per Share is projected to increase slightly based on the last few years of reporting. The current year's Inventory Turnover is expected to grow to 2.22, whereas Price To Sales Ratio is forecasted to decline to 3.76.
| 2022 | 2023 | 2024 | 2025 (projected) | Days Sales Outstanding | 70.08 | 96.63 | 81.95 | 65.86 | PTB Ratio | 1.95 | 2.95 | 3.77 | 3.58 |
Y MAbs fundamentals Correlations
Click cells to compare fundamentals
Y MAbs Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Y MAbs fundamentals Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Ptb Ratio | 18.77 | 3.89 | 1.95 | 2.95 | 3.77 | 3.58 | |
| Book Value Per Share | 2.64 | 4.17 | 2.5 | 2.31 | 2.08 | 2.41 | |
| Free Cash Flow Yield | (0.046) | (0.15) | (0.36) | (0.0915) | (0.0453) | (0.0475) | |
| Operating Cash Flow Per Share | (2.27) | (2.37) | (1.74) | (0.62) | (0.35) | (0.37) | |
| Pb Ratio | 18.77 | 3.89 | 1.95 | 2.95 | 3.77 | 3.58 | |
| Free Cash Flow Per Share | (2.28) | (2.4) | (1.74) | (0.62) | (0.35) | (0.37) | |
| Roic | (1.02) | (0.62) | (0.83) | (0.24) | (0.32) | (0.34) | |
| Net Income Per Share | (2.95) | (1.3) | (2.2) | (0.49) | (0.67) | (0.7) | |
| Payables Turnover | 0.24 | 0.19 | 0.53 | 1.88 | 2.29 | 2.4 | |
| Cash Per Share | 2.86 | 4.2 | 2.42 | 1.8 | 1.52 | 1.44 | |
| Pocfratio | (21.77) | (6.83) | (2.81) | (10.93) | (22.09) | (23.19) | |
| Pfcf Ratio | (21.73) | (6.76) | (2.81) | (10.93) | (22.09) | (23.19) | |
| Days Payables Outstanding | 1.6K | 2.0K | 683.74 | 193.75 | 159.44 | 151.47 | |
| Income Quality | 0.91 | 0.76 | 1.86 | 0.79 | 1.27 | 0.53 | |
| Ev To Operating Cash Flow | (20.56) | (5.09) | (1.44) | (8.1) | (17.86) | (18.75) | |
| Pe Ratio | (16.78) | (12.42) | (2.21) | (13.89) | (11.7) | (12.29) | |
| Return On Tangible Assets | (0.9) | (0.27) | (0.7) | (0.17) | (0.25) | (0.26) | |
| Ev To Free Cash Flow | (20.52) | (5.04) | (1.44) | (8.1) | (17.86) | (18.75) | |
| Earnings Yield | (0.0596) | (0.0805) | (0.45) | (0.072) | (0.0855) | (0.0897) | |
| Net Debt To E B I T D A | 0.93 | 3.27 | 1.1 | 3.1 | 2.13 | 2.24 | |
| Current Ratio | 6.26 | 7.26 | 4.61 | 5.52 | 4.16 | 3.95 | |
| Tangible Book Value Per Share | 2.64 | 4.13 | 2.43 | 2.25 | 2.02 | 3.28 | |
| Shareholders Equity Per Share | 2.64 | 4.17 | 2.5 | 2.31 | 2.08 | 2.41 | |
| Debt To Equity | 0.0376 | 0.0202 | 0.0162 | 0.0141 | 0.008913 | 0.008467 | |
| Graham Net Net | 2.19 | 3.65 | 1.97 | 1.63 | 1.3 | 1.24 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Y mAbs Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Y MAbs. If investors know YMAB will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Y MAbs listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.64) | Revenue Per Share | Quarterly Revenue Growth 0.134 | Return On Assets | Return On Equity |
The market value of Y mAbs Therapeutics is measured differently than its book value, which is the value of YMAB that is recorded on the company's balance sheet. Investors also form their own opinion of Y MAbs' value that differs from its market value or its book value, called intrinsic value, which is Y MAbs' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Y MAbs' market value can be influenced by many factors that don't directly affect Y MAbs' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Y MAbs' value and its price as these two are different measures arrived at by different means. Investors typically determine if Y MAbs is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Y MAbs' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.